We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 1-12 of 12 results

  1. Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study

    Studies investigating the safety of IgPro10 (Privigen ® , CSL Behring, King of Prussia, PA, USA) in Japanese patients with primary immunodeficiency...

    Tomohiro Morio, Kenji Gotoh, ... Mikhail A. Rojavin in International Journal of Hematology
    Article 18 March 2021

  3. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review

    There are two major clinical subsets of scleroderma: (i) systemic sclerosis (SSc) is a complex systemic autoimmune disorder characterized by...

    Ming Zhao, Jiali Wu, ... Qian** Lu in Clinical Reviews in Allergy & Immunology
    Article 15 January 2021

  5. Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates

    Background

    Recurrent and persistent infections are known to affect airways of patients with Primary Immunodeficiency despite appropriate replacement...

    Cédric Vonarburg, Marius Loetscher, ... Adrian W. Zuercher in Respiratory Research
    Article Open access 22 May 2019

  6. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial

    Background

    Subcutaneous administration of Ig (SCIg) has gained popularity as an alternative route of administration but has never been rigorously...

    Ivo N. van Schaik, Nan van Geloven, ... Ingemar S. J. Merkies in Trials
    Article Open access 25 July 2016

  8. Nervenregeneration mit IVIG

    Dagmar Jäger-Becker in InFo Neurologie & Psychiatrie
    Article 25 January 2016

  11. Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency

    Background and Objectives: Immunoglobulin replacement is a standard therapy for patients with primary immunodeficiencies. Subcutaneous administration...

    Richard L. Wasserman, Isaac Melamed, ... Joseph A. Church in Clinical Pharmacokinetics
    Article 01 June 2011

  12. Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a Practical approach

    To reduce the risk of infection in adults and children with primary immunodeficiencies, replacement therapy with IgG, which can be administered to...

    S. Jolles, J. W. Sleasman in Advances in Therapy
    Article Open access 14 June 2011
Did you find what you were looking for? Share feedback.